These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Tomalik-Scharte D; Fuhr U; Hellmich M; Frank D; Doroshyenko O; Jetter A; Stingl JC Drug Metab Dispos; 2011 May; 39(5):927-32. PubMed ID: 21270106 [TBL] [Abstract][Full Text] [Related]
5. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application. Rosak C; Hofmann U; Paulwitz O Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790 [TBL] [Abstract][Full Text] [Related]
6. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. Bakiner O; Ertorer ME; Bozkirli E; Tutuncu NB; Demirag NG Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302 [TBL] [Abstract][Full Text] [Related]
7. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Niemi M; Leathart JB; Neuvonen M; Backman JT; Daly AK; Neuvonen PJ Clin Pharmacol Ther; 2003 Oct; 74(4):380-7. PubMed ID: 14534525 [TBL] [Abstract][Full Text] [Related]
8. Severe hypoglycemia from clarithromycin-repaglinide drug interaction. Khamaisi M; Leitersdorf E Pharmacotherapy; 2008 May; 28(5):682-4. PubMed ID: 18447665 [TBL] [Abstract][Full Text] [Related]
9. [Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients]. Landgraf R MMW Fortschr Med; 2000 Jul; 142(28-29):29-30. PubMed ID: 10959157 [TBL] [Abstract][Full Text] [Related]
10. Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient. Roustit M; Blondel E; Villier C; Fonrose X; Mallaret MP Ann Pharmacother; 2010 Apr; 44(4):764-7. PubMed ID: 20197475 [TBL] [Abstract][Full Text] [Related]
11. Hypoglycemia probably due to accidental intake of repaglinide. Lee IT; Sheu WH; Lin SY Chang Gung Med J; 2002 Nov; 25(11):783-6. PubMed ID: 12553369 [TBL] [Abstract][Full Text] [Related]
12. Liquid chromatography-tandem mass spectrometry simultaneous determination of repaglinide and metformin in human plasma and its application to bioequivalence study. Liang XR; Dai XJ; Zhang YF; Ding JF; Chen XY; Zhong DF Yao Xue Xue Bao; 2013 Apr; 48(4):547-53. PubMed ID: 23833944 [TBL] [Abstract][Full Text] [Related]
13. Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia. Ambavane V; Patil R; Ainapure SS J Postgrad Med; 2002; 48(3):246-8. PubMed ID: 12432213 [No Abstract] [Full Text] [Related]
14. Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus. Jain S; Saraf S J Diabetes; 2009 Mar; 1(1):29-35. PubMed ID: 20923517 [TBL] [Abstract][Full Text] [Related]
15. The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes. Owens D J Assoc Physicians India; 2001 Jan; 49 Spec No():54-61. PubMed ID: 11235607 [No Abstract] [Full Text] [Related]
16. Pharmacokinetics of repaglinide in subjects with renal impairment. Marbury TC; Ruckle JL; Hatorp V; Andersen MP; Nielsen KK; Huang WC; Strange P Clin Pharmacol Ther; 2000 Jan; 67(1):7-15. PubMed ID: 10668848 [TBL] [Abstract][Full Text] [Related]
17. The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency. Østergård T; Degn KB; Gall MA; Carr RD; Veldhuis JD; Thomsen MK; Rizza RA; Schmitz O J Clin Endocrinol Metab; 2004 Jan; 89(1):297-302. PubMed ID: 14715864 [TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier. Yin LF; Huang SJ; Zhu CL; Zhang SH; Zhang Q; Chen XJ; Liu QW Drug Dev Ind Pharm; 2012 Nov; 38(11):1371-80. PubMed ID: 22296267 [TBL] [Abstract][Full Text] [Related]
19. Repaglinide induced acute hepototoxicity. Jaiswal S; Mehta R; Musuku M; Tran L; McNamee W JNMA J Nepal Med Assoc; 2009; 48(174):162-4. PubMed ID: 20387361 [TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic modelling of repaglinide in healthy volunteers by using Non-Parametric Adaptive Grid Algorithm. Ruzilawati AB; Mohd Suhaimi AW; Gan SH J Clin Pharm Ther; 2010 Feb; 35(1):105-12. PubMed ID: 20175819 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]